| Vol. 13.19 – 17 May, 2022 |
| |
|
|
Rapid Acceleration of KRAS-Mutant Pancreatic Carcinogenesis via Remodeling of Tumor Immune Microenvironment by PPARδ | Investigators showed that peroxisome proliferator-activated receptor-delta (PPARδ), a lipid nuclear receptor, was upregulated in pancreatic intraepithelial neoplasia lesions in humans and mice. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
Cargo Receptor Surf4 Regulates Endoplasmic Reticulum Export of Proinsulin in Pancreatic β-Cells | Scientists demonstrated that Surf4, a cargo receptor homolog, regulated the endoplasmic reticulum (ER) export of proinsulin via its recruitment to ER exit sites. [Communications Biology] |
|
|
|
St13 Protects against Disordered Acinar Cell Arachidonic Acid Pathway in Chronic Pancreatitis | St13, a co-chaperone protein, was investigated whether it constituted a novel regulatory target in chronic pancreatitis. [Journal of Translational Medicine] |
| |
|
|
A p300/GATA6 Axis Determines Differentiation and Wnt Dependency in Pancreatic Cancer Models | Researchers performed in vivo CRISPR screens in PORCN inhibitor-sensitive RNF43-mutant pancreatic cancer xenografts. [Journal of Clinical Investigation] |
|
|
|
HOXA10 Promote Pancreatic Cancer Progression via Directly Activating Canonical NF-κB Signaling Pathway | Immunohistochemistry assays were applied and demonstrated the relationship between homeobox A10 (HOXA10) expression and PDAC progression. [Carcinogenesis] |
|
|
|
RyR2/IRBIT Regulates Insulin Gene Transcript, Insulin Content, and Secretion in the Insulinoma Cell Line INS-1 | Insulin content, basal and 7.5 mM glucose-stimulated insulin secretion were reduced in RyR2KO and IRBITKO cells compared to controls. [Scientific Reports] |
|
|
|
Terpenoids from Nardostachys jatamansi and Their Cytotoxic Activity against Human Pancreatic Cancer Cell Lines | Compound epoxynardosinone exhibited significant cytotoxicity against CAPAN-2 cell lines with IC50 value of 2.60 ± 1.85 μM. 1-Hydroxylaristolone displayed comparable cytotoxicity on CFPAC-1 cell lines, compared to Taxol. [Phytochemistry] |
|
|
|
Coix Seed Oil Regulates Mitochondrial Functional Damage to Induce Apoptosis of Human Pancreatic Cancer Cells via the PTEN/PI3K/AKT Signaling Pathway | Researchers investigated the possible mechanism of coix seed oil induction of pancreatic cancer cell apoptosis and regulating mitochondrial functional damage. [Molecular Biology Reports] |
|
|
|
SQLE Inhibition Suppresses the Development of Pancreatic Ductal Adenocarcinoma and Enhances Its Sensitivity to Chemotherapeutic Agents In Vitro | Investigators explored the function of seven important enzymes involved in cholesterol biosynthesis, especially squalene epoxidase (SQLE) in PDAC therapy. [Molecular Biology Reports] |
|
|
|
|
The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer | Scientists review researches on the role of feedback loops in the progression of pancreatic cancer, and summarize the connection between feedback loops and several signaling pathways in pancreatic cancer, as well as recent advances in the intervention of feedback loops in pancreatic cancer treatment. [Frontiers in Oncology] |
|
|
|
The Roles of MicroRNA in Pancreatic Cancer Progression | The authors review the recent developments in miRNAs and their target role in the development, metastasis, migration, and invasion of PDAC. [Cancer Investigation] |
|
|
|
|
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes | NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. [NexImmune, Inc.] |
|
|
|
BC Researchers Launching Clinical Trial for First Genetically Engineered Stem Cell-Based Therapy for Type 1 Diabetes | Researchers from the UBC Faculty of Medicine and Vancouver Coastal Health have received $1 million from Canada’s Stem Cell Network to conduct research and a clinical trial for one of the world’s first genetically engineered cell replacement therapies for type 1 diabetes. [The University of British Columbia] |
|
|
|
|
| 7 – 8 November, 2022 London, England, United Kingdom |
|
|
|
|
|
|
| Steno Diabetes Center – Herlev, Denmark |
|
|
|
| Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| Cincinnati Childrens – Cincinnati, Ohio, United States |
|
|
|
|
|